share_log
Reuters ·  May 7 08:55
Moleculin Biotech: Annamycin in Combination With Cytarabine (Annarac) Achieves Crc Rate of 62% (54% Cr) in 1(St) and 2(Nd) Line Aml Subjects (N=13)
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment